49 results
6-K
EX-99.1
LEGN
Legend Biotech Corp
3 Jun 24
Current report (foreign)
4:05pm
patients including those with ongoing neurologic events at the time of death or data cut-off. Of patients with ICANS, 97% (35/36) had CRS. The onset … of parkinsonism was 243.5 days (range: 62 to 720 days) in all patients including those with ongoing neurologic events at the time of death or data cut
6-K
EX-99.1
LEGN
Legend Biotech Corp
23 May 24
Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
5:00pm
(range: 1 to 1229 days) in all patients including those with ongoing neurologic events at the time of death or data cut-off. Of patients with ICANS … events at the time of death or data cut-off. The onset of parkinsonism occurred after CRS for all patients and after ICANS for 6 patients.
Parkinsonism
6-K
EX-99.1
LEGN
Legend Biotech Corp
22 Apr 24
Current report (foreign)
1:06pm
). Median duration of ICANS was 6 days (range: 1 to 1229 days) in all patients including those with ongoing neurologic events at the time of death or data cut … those with ongoing neurologic events at the time of death or data cut-off. The onset of parkinsonism occurred after CRS for all patients and after
6-K
EX-99.1
LEGN
Legend Biotech Corp
8 Apr 24
Current report (foreign)
7:03am
duration of ICANS was 6 days (range: 1 to 1229 days) in all patients including those with ongoing neurologic events at the time of death or data cut-off … with ongoing neurologic events at the time of death or data cut-off. The onset of parkinsonism occurred after CRS for all patients and after ICANS for 6
6-K
EX-99.1
4gvazgg ph03
15 Mar 24
FDA ODAC votes 11 to 0 supporting favorable risk-benefit assessment of CARVYKTI based on results from the Phase 3 CARITUDE-4 study
3:18pm
6-K
EX-99.1
iq5jkiydx
23 Feb 24
Current report (foreign)
7:16am
6-K
EX-99.1
2e8fwqf7 t8j5kzf9
11 Dec 23
Legend Biotech Corporation 6-K
7:32pm
6-K
EX-99.1
dro q4bymt70xiu9w
6 Jun 23
Legend Biotech Corporation 6-K
4:44pm
6-K
EX-99.1
6bxxe98mo 06vmpvz2
5 Jun 23
Legend Biotech 6-K
11:17am
6-K
EX-99.1
mmhancc 5kfxhu
25 May 23
Legend Biotech Corporation 6-K
8:30am
6-K
EX-99.1
8iyt s8ex8axd3gc
16 May 23
Legend Biotech Corporation 6-K
8:39am
6-K
EX-99.1
q68dh ohy6
21 Apr 23
Legend Biotech Corporation 6-K
8:30am
6-K
EX-99.1
3o4pnz7auw4lj
3 Nov 22
Legend Biotech Corporation 6-K
4:09pm
6-K
EX-10.1
xy7 908dz5icbl0jdk
3 Oct 22
Legend Biotech Corporation 6-K
4:02pm
6-K
EX-99.1
zgq4gs47d zgywf8uip0
27 Sep 22
Legend Biotech Corp. 6-K
9:17am
6-K
EX-10.1
m1hdlh
4 Aug 22
Legend Biotech Appoints Three New Directors and Elects New Chairman of the Board
4:18pm
6-K
EX-1.1
mkl95m8k udib0pp9
27 Jul 22
Announces Pricing of Public Offering
4:35pm